Table 3.
Elimination study: Demographic characteristics and clinical parameters of both treatment groups, before and after periodontal therapy.
| Treatment groups |
||||
|---|---|---|---|---|
| Variables | Time | SRP (n = 20) | SRP+ MTZ + AMX (n = 20) | p-value |
| Gender (F/M) | Baseline | 16/4 | 12/8 | 0.300# |
| Age (Mean ± SD, years) | Baseline | 44.8 ± 8.9 | 46.2 ± 8.9 | 0.473* |
| PD (Mean ± SD, mm) | Baseline | 3.88 ± 0.64 | 3.70 ± 0.66 | 0.514* |
| CAL (Mean ± SD, mm) | Baseline | 4.25 ± 0.74 | 4.15 ± 0.89 | 0.375* |
| Mean number (± SD) of sites with PD ≥5 mm | Baseline | 38.8 ± 21.6 A | 33.0 ± 20.0 A | 0.089* |
| 1 year | 14.5 ± 10.2 B, a | 4.1 ± 4.8 B, b | <0.0001* | |
| Number and % of patients achieving the clinical endpoint for treatment, i.e. < 4 sites PD > 5 mm [29]. | 1 year | 2 (10.0%)a | 14 (70.0%)b | <0.0001# |
The statistical significance of differences between groups at baseline and at 1-year post-treatment was assessed by the Mann-Whitney (*) test or the Chi-square test (#). Different lowercase letters indicate significant differences between groups, p < 0.05.
The statistical significance of differences within each group for the mean number of sites with PD ≥5 mm (between baseline and 1 year) was assessed by the Wilcoxon test. Different capital letters indicate significant differences between time points, p < 0.05.
SRP, scaling and root planing; MTZ, metronidazole; AMX, amoxicillin; PD, probing depth, CAL, clinical attachment level; SD: Standard deviation.